ClinicalTrials.gg
CompletedNCT02474069GAINUpdated Jul 5, 2019Results posted

Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis

A Phase 3 interventional study of Secukinumab in Moderate to Severe Plaque-type Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 89 sites in Germany. Per ClinicalTrials.gov, last updated 2019-07-05.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
772
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies testing secukinumab in Skin Diseases — none open to participants now, none under way, none of them phase 3. secukinumab · Skin Diseases.

Enrollment
Largest of 10
772 · median 156
Started
2015
with 1 other
Phase 3
7 of 10
none open now
Registered
7th of 10
by date
Lead sponsor
9 of 10
Novartis Pharmaceuticals

Among the 10 studies testing secukinumab in Skin Diseases, this one has the largest enrollment, is one of 2 that started in 2015, is one of 7 in phase 3, and was the 7th registered.

Skin Diseases

497 studies on the registry are indexed under Skin Diseases; 78 are open to participants now.

Browse Skin Diseases studies →

Open to participants now

None of the 10 studies testing secukinumab in Skin Diseases is open now. The open studies under Skin Diseases, anywhere →

About secukinumab

secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Skin Diseases studies recruiting now, 27 (49%) set no upper age limit and 18 (33%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing secukinumab in Skin Diseases as a file.
02

Study summary

This study is designed to support the optimal use of secukinumab by providing data to refine guidance on dosing flexibility in patients with psoriasis. The purpose of the study is to explore the effects of dosage interval shorteng to achieve PASI 90 at week 32 for patients who had less than almost clear skin at week 16.

03

Conditions studied

  • Moderate to Severe Plaque-type Psoriasis

Keywords

  • skin condition
  • skin disease
  • itching condition
  • psoriasis vulgaris
  • relapsing psoriasis
  • remitting psoriasis
  • immune-mediated systemic disease
  • skin lesions, red skin lesions
  • scaly patches
  • papules, plaques
  • itching
  • auto-immune
  • plaque-type psoriasis
  • plaque
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects eligible for inclusion in this study must fulfill all of the following criteria:

  1. Subjects must be able to understand and communicate with the investigator and must give a written, signed and dated before any study related activity is performed and who are willing and capable to comply with all study procedures.
  2. Men or women at least 18 years of age at time of screening.
  3. Chronic plaque type psoriasis diagnosed for at least 6 months prior to baseline
  4. Moderate to severe plaque type psoriasis at baseline derived from the European consensus (Mrowietz et al., 2011): BSA (Body Surface Area) >10% and PASI>10 and DLQI>10.
  5. Candidates for biologic therapy who failed to respond to, or who had a to or were intolerant to previous conventional systemic therapies.
  6. According to local guidelines, to exclude chest infection before initiation of a biologic immunomodulating therapy, it is necessary to have obtained an image of the chest (X-ray, computerized tomography or magnetic resonance imaging) within 12 weeks prior to screening and have this evaluated by a qualified physician.

Exclusion criteria

Exclusion Criteria:

  1. Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and guttata psoriasis).
  2. Drug-induced psoriasis (i.e., new onset or current exacerbation from beta-blockers, calcium channel inhibitors or lithium).
  3. Ongoing use of prohibited psoriasis and non-psoriasis treatments. have to be adhered to.
  4. Subjects not willing to limit UV light exposure (e.g., sunbathing and/or the use of tanning devices) during the course of the study.
  5. Use of other drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer.
  6. Previous exposure to secukinumab (AIN457) or any other biologic drug directly targeting IL-17A or the IL-17A receptor (e.g. brodalumab, ixekizumab).
  7. History of to any of the study drugs or to drugs with similar chemical structures.
  8. Study personnel or first degree relatives of investigator(s) must not be included in the study.
  9. Women who are pregnant or breast feeding (pregnancy defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/ml)) who are menstruating and capable of becoming pregnant* and not practicing a medically approved method of (Pearl Index \<1**) during and up to at least 4 weeks after the end of treatment. A negative pregnancy test (serum) for all women and for girls entering menarche is required with sufficient lead time before inclusion

    *definition of : 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels >40 mIU/m or 6 weeks post- surgical bilateral oophorectomy with or without hysterectomy

    **examples of particularly reliable methods with Pearl Index (PI) \<1, according to guidelines of Deutsche Gesellschaft für Gynakologie und Geburtshilfe:

    • hormonal oral contraception (Combination of estrogen and gestagen, PI=0.1-0.9) hormonal vaginal ring (combination of estrogen and gestagen, PI=0.65 uncorr.; 0.4 corr.)
    • hormonal transdermal patch (combination of estrogen and gestagen, PI= 0.72 uncorr.; 0.9 corr.)
    • Estrogen-free ovulation inhibitors containing desogestrel (PI=0.14)
    • Implanted hormones containing etonogestrel (PI=0-0.08)
    • Injectable 3-month depot progestins (PI=0.3-1.4; 0.88 corr.)
    • Intra-uterine progestine device (synthetic progestin containing IUDs,PI=0.16)
    • Oral contraceptives without estrogen (e.g. "mini-pills"), nonsynthetic progesterone only IUDs, female condoms, cervical shield, periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
  10. Active ongoing inflammatory diseases other than psoriasis that might confound the evaluation of the benefit of secukinumab therapy. Patients with psoriatic arthritis are not excluded.
  11. Underlying condition (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal) which in the opinion of the investigator significantly immunocompromises the subject and/or places the subject at unacceptable risk for receiving an immunomodulatory therapy.
  12. Subjects with preexisting or recent-onset central or peripheral nervous system demyelinating disorders at discretion of the investigator.
  13. Significant medical problems, including but not limited to the following: uncontrolled hypertension (≥160 systolic and/or 95 diastolic mmHg), congestive heart failure [ status of class III or IV].
  14. Subjects with a serum creatinine level exceeding 2.0 mg/dl (176.8μmol/l) at screening.
  15. Screening total white blood cell (WBC) count \<2,500/μl, or \<100,000/μl or neutrophils \<1,500/μl or \<8.5 g/dl.
  16. Active systemic infections during the last two weeks (exception: common cold) prior to screening or any infection that reoccurs on a regular basis.
  17. History of an ongoing, chronic or recurrent infectious disease including recurrent respiratory and/or urinary tract infections or evidence of tuberculosis infection as defined by a positive QuantiFERON TB-Gold test at screening. Subjects with a positive or indeterminate QuantiFERON TB-Gold test may participate in the study if further full tuberculosis work up (according to local practice/guidelines) completed at least 12 weeks prior to first study drug administration establishes conclusively that the subject has no evidence of active tuberculosis. If presence of latent tuberculosis is established, then treatment must have been initiated and maintained according to local country guidelines for at least 4 weeks prior to screening.
  18. Past medical history record of infection with (HIV), or prior to screening.
  19. History of lymphoproliferative disease or any known or history of malignancy of any organ system within the past 5 years (except for skin Bowen's disease, or basal cell carcinoma or actinic keratoses that have been treated with no evidence of recurrence in the past 12 weeks; carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed).
  20. Current severe progressive or uncontrolled disease which in the judgment of the clinical investigator renders the subject unsuitable for the trial or puts the subject at increased risk.
  21. Inability or unwillingness to undergo repeated venipuncture (e.g. because of poor tolerability or lack of access to veins).
  22. Any medical or psychiatric condition which, in the investigator's opinion, would preclude the participant from adhering to the protocol or completing the study per protocol.
  23. History or evidence of ongoing alcohol or drug abuse, within the last six months before screening.
  24. Plans for administration of during the study period or 6 weeks prior to screening.

No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible subjects.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
772 participants (actual)

Study arms

  • Active comparator
    Secukinumab Interval Shortening

    Drug: Secukinumab

  • Active comparator
    Secukinumab 4-weekly

    Drug: Secukinumab

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With PASI 90 Response at Week 32

    Number of participants with at least 90% improvement from baseline. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

    Time frame: at 32 weeks

  2. Number of Participants With PASI 90 Response at Week 32 for PPS

    Number of participants with at least 90% improvement from baseline. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

    Time frame: at week 32

Secondary outcomes

  1. Selection Phase: Number of Participants Achieving (Psoriasis Area and Severity Index Score)PASI 50, 75, 90, 100

    Number of participants with at least 50, 75, 90 or 100% improvement from baseline. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

    Time frame: at weeks 1, 2, 3, 4, 8, 12 and 16

  2. Comparative Dose Phase: Number of Participants Achieving Psoriasis Area and Severity Index Score (PASI) 90 and 100

    Number of participants with at least 90 or 100% improvement from baseline. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

    Time frame: at weeks 18, 22, 30, 32

  3. Selection Phase:Summary of PASI Total Score

    PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

    Time frame: at weeks 1,2,3,4,8, 12, 16

  4. Comparative Dose Phase: Summary of PASI Total Score

    PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

    Time frame: Weeks 18, 22, 26, 30 and 32

  5. Number of Patients Achieving Dermatology Life Quality Index (DLQI) Scores of 0 or 1 by Visits in the CDP

    The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. The DLQI was designed to assess health-related quality of life (HRQoL) in adult patients with skin diseases including psoriasis.

    Time frame: Weeks 4, 16, 18, 22, 26, 30, 32

  6. Number of Patients Achieving DLQI Total Score <= 5 in the CDP

    The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment.

    Time frame: Weeks 4, 16, 18, 22, 26, 30, 32

  7. Selection Phase: Number of Patients Achieving Investigator Global Assessment (IGA) 0 or 1

    The IGA scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe and 5 = very severe.

    Time frame: Weeks 4, 16

  8. Comparative Dose Phase: Number of Patients Achieving Investigator Global Assessment (IGA) 0 or 1

    The IGA scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe and 5 = very severe.

    Time frame: Weeks 18, 22, 26, 30, 32

  9. Selection Phase: Summary of IGA Score

    The IGA scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe and 5 = very severe.

    Time frame: Weeks 4, 16

  10. Comparative Dose Phase:Summary of IGA Score

    The IGA scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe and 5 = very severe.

    Time frame: Weeks 18, 22, 26, 30, 32

07

Results

Posted Jul 5, 2019

Participant flow

860 screened (not shown here). In selection phase (SP), 772 received 300 mg s.c. open-label secukinumab at baseline to wk 12. Those who did not achieve ≥Psoriasis Area and Severity Index (PASI) 75 at wk 16 discontinued. Those who had ≤ clear or almost clear skin (≥PASI75 but not PASI90) rolled over into double blind comparative dosing phase (CDP).

Selection Phase (SP)
Participant flow — Selection Phase (SP)
MilestoneSP - Secukinumab 300 mg s.c. (4-weekly)CDP - Secukinumab 300 mg s.c. (4-weekly)CDP - Secukinumab 300 mg s.c. (2-weekly)
Started77200
Completed74900
Not completed2300
Withdrew: Adverse event800
Withdrew: Lack of efficacy100
Withdrew: Lost to follow-up400
Withdrew: Physician decision100
Withdrew: Protocol violation100
Withdrew: No longer requires treatment100
Withdrew: Technical problem100
Withdrew: Withdrawal by subject300
Withdrew: Withdrawal of informed consent300
Comparative Dosing Phase (CDP)
Participant flow — Comparative Dosing Phase (CDP)
MilestoneSP - Secukinumab 300 mg s.c. (4-weekly)CDP - Secukinumab 300 mg s.c. (4-weekly)CDP - Secukinumab 300 mg s.c. (2-weekly)
Started0162163
Completed0153157
Not completed096
Withdrew: Adverse event032
Withdrew: Lost to follow-up041
Withdrew: Withdrawal by subject001
Withdrew: Withdrawal of informed consent022

Outcome measures

PrimaryNumber of Participants With PASI 90 Response at Week 32

Number of participants with at least 90% improvement from baseline. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

Time frame:
at 32 weeks
Reported as:
Number · participants
Number of Participants With PASI 90 Response at Week 32
participantsCDP - Secukinumab 300 mg s.c. (4-weekly)CDP - Secukinumab 300 mg s.c. (2-weekly)
Number of Participants With PASI 90 Response at Week 3293105
Statistical analysis
  • CDP - Secukinumab 300 mg s.c. (4-weekly) vs CDP - Secukinumab 300 mg s.c. (2-weekly) · ANCOVA · p = 0.087 · Odds ratio (or): 0.64 · 95% CI 0.39 to 1.07
PrimaryNumber of Participants With PASI 90 Response at Week 32 for PPS

Number of participants with at least 90% improvement from baseline. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

Time frame:
at week 32
Reported as:
Number · participants
Number of Participants With PASI 90 Response at Week 32 for PPS
participantsCDP - Secukinumab 300 mg s.c. (4-weekly)CDP - Secukinumab 300 mg s.c. (2-weekly)
Number of Participants With PASI 90 Response at Week 32 for PPS8185
Statistical analysis
  • CDP - Secukinumab 300 mg s.c. (4-weekly) vs CDP - Secukinumab 300 mg s.c. (2-weekly) · ANCOVA · p = 0.281 · Odds ratio (or): 0.74 · 95% CI 0.43 to 1.28
SecondarySelection Phase: Number of Participants Achieving (Psoriasis Area and Severity Index Score)PASI 50, 75, 90, 100

Number of participants with at least 50, 75, 90 or 100% improvement from baseline. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

Time frame:
at weeks 1, 2, 3, 4, 8, 12 and 16
Reported as:
Number · Number of participants
Selection Phase: Number of Participants Achieving (Psoriasis Area and Severity Index Score)PASI 50, 75, 90, 100
Number of participantsSP - Secukinumab 300 mg s.c. (4-weekly)
Week 1, PASI 5043
Week 1, PASI 753
Week 1, PASI 900
Week 1, PASI 1000
Week 2, PASI 50232
week 2, PASI 7525
Week 2, PASI 905
Week 2, PASI 1001
Week 3, PASI 50468
Week 3, PASI 75128
Week 3, PASI 9022
Week 3, PASI 1003
Week 4, PASI 50591
Week 4, PASI 75281
Week 4, PASI 9071
Week 4, PASI 10012
Week 8, PASI 50718
Week 8, PASI 75538
Week 8, PASI 90266
Week 8, PASI 10070
Week 12, PASI 50733
Week 12, PASI 75611
Week 12, PASI 90370
Week 12, PASI 100110
Week 16, PASI 50732
Week 16, PASI 75698
Week 16, PASI 90363
Week 16, PASI 100124
SecondaryComparative Dose Phase: Number of Participants Achieving Psoriasis Area and Severity Index Score (PASI) 90 and 100

Number of participants with at least 90 or 100% improvement from baseline. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

Time frame:
at weeks 18, 22, 30, 32
Reported as:
Number · Number of participants
Comparative Dose Phase: Number of Participants Achieving Psoriasis Area and Severity Index Score (PASI) 90 and 100
Number of participantsCDP - Secukinumab 300 mg s.c. (4-weekly)CDP - Secukinumab 300 mg s.c. (2-weekly)
Week 18, PASI 904236
Week 18, PASI 10011
Week 22, PASI 907067
Week 22, PASI 10099
Week 26, PASI 908594
Week 26, PASI 100914
Week 30, PASI 9093104
Week 30, PASI 1001719
Week 32, PASI 9093105
Week 32, PASI 1002226
SecondarySelection Phase:Summary of PASI Total Score

PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

Time frame:
at weeks 1,2,3,4,8, 12, 16
Reported as:
Mean · Score on a Scale
Selection Phase:Summary of PASI Total Score
Score on a ScaleSP - Secukinumab 300 mg s.c. (4-weekly)
week 118.78 ± 9.629
week 214.32 ± 8.435
week 310.69 ± 7.372
week 48.12 ± 6.494
week 84.41 ± 4.544
Week 123.34 ± 3.833
Week 162.90 ± 3.816
SecondaryComparative Dose Phase: Summary of PASI Total Score

PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

Time frame:
Weeks 18, 22, 26, 30 and 32
Reported as:
Mean · Score on a Scale
Comparative Dose Phase: Summary of PASI Total Score
Score on a ScaleCDP - Secukinumab 300 mg s.c. (4-weekly)CDP - Secukinumab 300 mg s.c. (2-weekly)
Week 183.71 ± 2.5323.59 ± 2.595
Week 223.24 ± 2.9473.07 ± 2.726
Week 262.85 ± 2.8522.68 ± 3.393
Week 302.83 ± 3.3392.34 ± 2.812
Week 322.84 ± 3.5522.11 ± 2.701
SecondaryNumber of Patients Achieving Dermatology Life Quality Index (DLQI) Scores of 0 or 1 by Visits in the CDP

The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. The DLQI was designed to assess health-related quality of life (HRQoL) in adult patients with skin diseases including psoriasis.

Time frame:
Weeks 4, 16, 18, 22, 26, 30, 32
Reported as:
Number · participants with DLQI score 0/1
Number of Patients Achieving Dermatology Life Quality Index (DLQI) Scores of 0 or 1 by Visits in the CDP
participants with DLQI score 0/1Secukinumab 300 mg s.c. (4-weekly)CDP - Secukinumab 300 mg s.c. (2-weekly)
Week 186558
Week 227073
Week 266983
Week 307589
Week 328296
SecondaryNumber of Patients Achieving DLQI Total Score <= 5 in the CDP

The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment.

Time frame:
Weeks 4, 16, 18, 22, 26, 30, 32
Reported as:
Number · participants
Number of Patients Achieving DLQI Total Score <= 5 in the CDP
participantsSecukinumab 300 mg s.c. (4-weekly)CDP - Secukinumab 300 mg s.c. (2-weekly)
Week 18109108
Week 22112117
Week 26116121
Week 30114127
Week 32117126
SecondarySelection Phase: Number of Patients Achieving Investigator Global Assessment (IGA) 0 or 1

The IGA scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe and 5 = very severe.

Time frame:
Weeks 4, 16
Reported as:
Number · Participants
Selection Phase: Number of Patients Achieving Investigator Global Assessment (IGA) 0 or 1
ParticipantsSP - Secukinumab 300 mg s.c. (4-weekly)
week 4150
week 16446
SecondaryComparative Dose Phase: Number of Patients Achieving Investigator Global Assessment (IGA) 0 or 1

The IGA scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe and 5 = very severe.

Time frame:
Weeks 18, 22, 26, 30, 32
Reported as:
Number · Participants
Comparative Dose Phase: Number of Patients Achieving Investigator Global Assessment (IGA) 0 or 1
ParticipantsCDP - Secukinumab 300 mg s.c. (4-weekly)CDP - Secukinumab 300 mg s.c. (2-weekly)
week 186768
week 228890
week 2687111
week 3097106
week 3298111
SecondarySelection Phase: Summary of IGA Score

The IGA scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe and 5 = very severe.

Time frame:
Weeks 4, 16
Reported as:
Mean · Score on a scale
Selection Phase: Summary of IGA Score
Score on a scaleSP - Secukinumab 300 mg s.c. (4-weekly)
Week 42.10 ± 0.790
Week 161.26 ± 0.875
SecondaryComparative Dose Phase:Summary of IGA Score

The IGA scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe and 5 = very severe.

Time frame:
Weeks 18, 22, 26, 30, 32
Reported as:
Mean · Score on a scale
Comparative Dose Phase:Summary of IGA Score
Score on a scaleCDP - Secukinumab 300 mg s.c. (4-weekly)CDP - Secukinumab 300 mg s.c. (2-weekly)
Week 181.63 ± 0.6191.64 ± 0.656
Week 221.46 ± 0.7331.42 ± 0.704
Week 261.48 ± 0.7581.30 ± 0.759
Week 301.33 ± 0.8481.27 ± 0.803
Week 321.30 ± 0.9251.13 ± 0.819

Adverse events

Collected over Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 1 year and 4 months.. Non-serious events are listed at a 0.0001% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SP-Secukinumab: AIN457 300 mg s.c. (4-weekly)—32/772 (4.1%)510/772 (66.1%)
CDP-Secukinumab: AIN457 300 mg s.c. (4-weekly)—8/162 (4.9%)85/162 (52.5%)
CDP-Secukinumab: AIN457 300 mg s.c. (2-weekly)—4/163 (2.5%)87/163 (53.4%)
Most frequent serious events
Showing 10 of 60
Most frequent serious events
EventSP-Secukinumab: AIN457 300 mg s.c. (4-weekly)CDP-Secukinumab: AIN457 300 mg s.c. (4-weekly)CDP-Secukinumab: AIN457 300 mg s.c. (2-weekly)
CHEST PAINGeneral disorders0/7721/1620/163
IMPAIRED HEALINGGeneral disorders0/7721/1620/163
ERYSIPELASInfections and infestations0/7721/1620/163
MASTOIDITISInfections and infestations0/7721/1620/163
PYODERMAInfections and infestations0/7721/1620/163
SINUSITISInfections and infestations0/7721/1620/163
CHEST INJURYInjury, poisoning and procedural complications0/7721/1620/163
CONTUSIONInjury, poisoning and procedural complications0/7721/1620/163
FALLInjury, poisoning and procedural complications0/7721/1620/163
WOUNDInjury, poisoning and procedural complications0/7721/1620/163
Most frequent other events
Showing 10 of 400
Most frequent other events
EventSP-Secukinumab: AIN457 300 mg s.c. (4-weekly)CDP-Secukinumab: AIN457 300 mg s.c. (4-weekly)CDP-Secukinumab: AIN457 300 mg s.c. (2-weekly)
NASOPHARYNGITISInfections and infestations168/77223/16227/163
HEADACHENervous system disorders60/7725/1625/163
DIARRHOEAGastrointestinal disorders34/7723/1621/163
PRURITUSSkin and subcutaneous tissue disorders32/7722/1620/163
FATIGUEGeneral disorders28/7724/1623/163
ARTHRALGIAMusculoskeletal and connective tissue disorders21/7724/1623/163
FOLLICULITISInfections and infestations13/7724/1622/163
ECZEMASkin and subcutaneous tissue disorders10/7724/1621/163
SCIATICANervous system disorders4/7721/1624/163
HYPERTENSIONVascular disorders8/7723/1624/163

Baseline characteristics

Age, Continuous
Age, Continuous(Years)SP - Secukinumab 300 mg s.c. (4-weekly
Mean45.8 ± 13.72
Sex/Gender, Customized
Sex/Gender, Customized(Participants)SP - Secukinumab 300 mg s.c. (4-weekly
Female222
Male550
08

Study locations

89 sites
  • Novartis Investigative Site
    Bad Bentheim, 48455, Germany
  • Novartis Investigative Site
    Berlin, 10247, Germany
  • Novartis Investigative Site
    Berlin, 10405, Germany
  • Novartis Investigative Site
    Berlin, 10437, Germany
  • Novartis Investigative Site
    Berlin, 10783, Germany
  • Novartis Investigative Site
    Berlin, 12437, Germany
  • Novartis Investigative Site
    Berlin, 13055, Germany
  • Novartis Investigative Site
    Berlin, 13086, Germany
  • Novartis Investigative Site
    Berlin, 13088, Germany
  • Novartis Investigative Site
    Berlin, 13125, Germany
  • Novartis Investigative Site
    Berlin, 13187, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Berlin, 13507, Germany
  • Novartis Investigative Site
    Berlin, 14052, Germany
  • Novartis Investigative Site
    Bielefeld, 33647, Germany
  • Novartis Investigative Site
    Blaubeuren, 89143, Germany
  • Novartis Investigative Site
    Blaustein, 89134, Germany
  • Novartis Investigative Site
    Bochum, 44803, Germany
  • Novartis Investigative Site
    Bonn, 53111, Germany
  • Novartis Investigative Site
    Borna, 04552, Germany
  • Novartis Investigative Site
    Darmstadt, 64283, Germany
  • Novartis Investigative Site
    Dresden, 01097, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Duelmen, 48249, Germany
  • Novartis Investigative Site
    Duisburg, 47166, Germany
  • Novartis Investigative Site
    Duren, 52349, Germany
  • Novartis Investigative Site
    Erlangen, 91054, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Frankfurt, 60590, Germany
  • Novartis Investigative Site
    Freiburg, 79098, Germany
  • Novartis Investigative Site
    Freiburg, 79100, Germany
  • Novartis Investigative Site
    Freising, 85354, Germany
  • Novartis Investigative Site
    Friedrichshafen, 88045, Germany
  • Novartis Investigative Site
    Garching, 85748, Germany
  • Novartis Investigative Site
    Germering, 82110, Germany
  • Novartis Investigative Site
    Giessen, 35390, Germany
  • Novartis Investigative Site
    Glückstadt, 25348, Germany
  • Novartis Investigative Site
    Goslar, 38640, Germany
  • Novartis Investigative Site
    Gottingen, 37075, Germany
  • Novartis Investigative Site
    Greifswald, 17475, Germany
  • Novartis Investigative Site
    Halle, 06108, Germany
  • Novartis Investigative Site
    Halle, 06120, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Hamburg, 20354, Germany
  • Novartis Investigative Site
    Hamburg, 22391, Germany
  • Novartis Investigative Site
    Hannover, 30159, Germany
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
  • Novartis Investigative Site
    Hildesheim, 31134, Germany
  • Novartis Investigative Site
    Ibbenbuehren, 49477, Germany
  • Novartis Investigative Site
    Ibbenbueren, 49477, Germany
  • Novartis Investigative Site
    Itzehoe, 25524, Germany
  • Novartis Investigative Site
    Jena, 07740, Germany
  • Novartis Investigative Site
    Kassel, 34125, Germany
  • Novartis Investigative Site
    Kiel, 24103, Germany
  • Novartis Investigative Site
    Kiel, 24105, Germany
  • Novartis Investigative Site
    Koeln, 50674, Germany
  • Novartis Investigative Site
    Langenau, 89129, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Lingen, 49809, Germany
  • Novartis Investigative Site
    Loehne, 32584, Germany
  • Novartis Investigative Site
    Luedenscheid, D 58511, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Muenchen, 81675, Germany
  • Novartis Investigative Site
    Muenster, 48143, Germany
  • Novartis Investigative Site
    Muenster, 48149, Germany
  • Novartis Investigative Site
    Munchen, 80335, Germany
  • Novartis Investigative Site
    München, 80469, Germany
  • Novartis Investigative Site
    Oberhausen, 46147, Germany
  • Novartis Investigative Site
    Osnabrueck, 49078, Germany
  • Novartis Investigative Site
    Pommelsbrunn, 91224, Germany
  • Novartis Investigative Site
    Potsdam, 14467, Germany
  • Novartis Investigative Site
    Quedlinburg, 06484, Germany
  • Novartis Investigative Site
    Remscheid, 42897, Germany
  • Novartis Investigative Site
    Rheinbach, 53359, Germany
  • Novartis Investigative Site
    Schweinfurt, 97421, Germany
  • Novartis Investigative Site
    Soest, 59494, Germany
  • Novartis Investigative Site
    Stade, 21682, Germany
  • Novartis Investigative Site
    Straubing, 94315, Germany
  • Novartis Investigative Site
    Stuttgart-Weilimdorf, 70499, Germany
  • Novartis Investigative Site
    Stuttgart, 70176, Germany
  • Novartis Investigative Site
    Tübingen, 72076, Germany
  • Novartis Investigative Site
    Ulm, 89081, Germany
  • Novartis Investigative Site
    Weißenfels, 06667, Germany
  • Novartis Investigative Site
    Wiesbaden, 65199, Germany
  • Novartis Investigative Site
    Wolfenbüttel, 38300, Germany
  • Novartis Investigative Site
    Wuerzburg, 97080, Germany
  • Novartis Investigative Site
    Wuppertal, 42105, Germany
  • Novartis Investigative Site
    Wuppertal, 42117, Germany
  • Novartis Investigative Site
    Wuppertal, 42349, Germany
09

References and documents

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2015 to primary completion in Sep 2016, 19 months.

Results were first posted in Jul 2019, 2 years 9 months after primary completion.

Of 58 industry-sponsored phase 3 interventional studies under Skin Diseases, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's 19 months is close to that.

Counting every sponsor, half of 60 studies reached it within 19 months; a quarter within 13 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2015
First posted
Jun 17, 2015
StartActual
Feb 8, 2015
Primary completionActual
Sep 15, 2016
CompletionActual
Sep 15, 2016
Results first posted
Jul 5, 2019
Last update
Jul 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02474069
Responsible party
Sponsor
First posted
Jun 17, 2015
Start date
Feb 8, 2015
Primary completion
Sep 15, 2016
Completion
Sep 15, 2016
Results posted
Jul 5, 2019
Last update
Jul 5, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion